Latest Insider Transactions at Biocryst Pharmaceuticals Inc (BCRX)
This section provides a real-time view of insider transactions for Biocryst Pharmaceuticals Inc (BCRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOCRYST PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOCRYST PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 30
2024
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
647
+0.85%
|
$5,176
$8.69 P/Share
|
|
Jun 24
2024
|
Amy E Mc Kee Director |
SELL
Open market or private sale
|
Direct |
8,600
-23.61%
|
$51,600
$6.32 P/Share
|
|
Jun 17
2024
|
Machelle Sanders Director |
SELL
Open market or private sale
|
Direct |
4,689
-14.46%
|
$28,134
$6.0 P/Share
|
|
Jun 14
2024
|
Theresa Heggie Director |
SELL
Open market or private sale
|
Direct |
6,698
-11.25%
|
$40,188
$6.11 P/Share
|
|
Jun 12
2024
|
Amy E Mc Kee Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+15.77%
|
-
|
|
Jun 12
2024
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+8.37%
|
-
|
|
Jun 12
2024
|
Machelle Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+17.38%
|
-
|
|
Jun 12
2024
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+10.28%
|
-
|
|
Jun 12
2024
|
Nancy J Hutson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+6.79%
|
-
|
|
Jun 12
2024
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+11.64%
|
-
|
|
Jun 12
2024
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+8.86%
|
-
|
|
Jun 12
2024
|
Steven K Galson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+15.77%
|
-
|
|
Jun 12
2024
|
George B Abercrombie Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+15.77%
|
-
|
|
May 31
2024
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
870
+1.62%
|
$5,220
$6.46 P/Share
|
|
May 31
2024
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
870
+1.27%
|
$5,220
$6.46 P/Share
|
|
May 30
2024
|
Alan G Levin Director |
BUY
Open market or private purchase
|
Direct |
7,861
+14.88%
|
$47,166
$6.36 P/Share
|
|
May 24
2024
|
Steve Aselage Director |
BUY
Open market or private purchase
|
Indirect |
2,500
+50.0%
|
$15,000
$6.4 P/Share
|
|
May 20
2024
|
Nancy J Hutson Director |
BUY
Open market or private purchase
|
Direct |
5,000
+5.45%
|
$30,000
$6.38 P/Share
|
|
May 20
2024
|
Vincent Milano Director |
BUY
Open market or private purchase
|
Direct |
15,000
+18.29%
|
$90,000
$6.25 P/Share
|
|
May 14
2024
|
Anthony Doyle Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
36,300
+11.98%
|
$181,500
$5.57 P/Share
|
|
May 14
2024
|
Helen M. Thackray Chief R&D Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+9.93%
|
$150,000
$5.86 P/Share
|
|
May 13
2024
|
Steven K Galson Director |
BUY
Open market or private purchase
|
Direct |
21,940
+29.85%
|
$109,700
$5.49 P/Share
|
|
May 13
2024
|
Alane P Barnes Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.64%
|
$25,000
$5.53 P/Share
|
|
May 13
2024
|
Charles K Gayer Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+8.89%
|
$150,000
$5.47 P/Share
|
|
May 13
2024
|
Jon P Stonehouse President & CEO |
BUY
Open market or private purchase
|
Direct |
30,000
+2.59%
|
$150,000
$5.55 P/Share
|
|
Mar 31
2024
|
Helen M. Thackray Chief R&D Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,525
-3.01%
|
$37,625
$5.08 P/Share
|
|
Feb 29
2024
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
999
+1.89%
|
$4,995
$5.63 P/Share
|
|
Feb 29
2024
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
999
+1.89%
|
$4,995
$5.63 P/Share
|
|
Jan 03
2024
|
Jon P Stonehouse President & CEO |
BUY
Bona fide gift
|
Indirect |
20,000
+33.33%
|
-
|
|
Jan 03
2024
|
Jon P Stonehouse President & CEO |
SELL
Bona fide gift
|
Direct |
20,000
-1.79%
|
-
|
|
Dec 19
2023
|
Jon P Stonehouse President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,089
-1.25%
|
$84,534
$6.05 P/Share
|
|
Dec 19
2023
|
Helen M. Thackray Chief R&D Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,580
-2.19%
|
$33,480
$6.05 P/Share
|
|
Dec 19
2023
|
Anthony Doyle Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,482
-1.08%
|
$14,892
$6.05 P/Share
|
|
Dec 19
2023
|
Charles K Gayer Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,482
-0.9%
|
$14,892
$6.05 P/Share
|
|
Dec 19
2023
|
Alane P Barnes Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,482
-0.84%
|
$14,892
$6.05 P/Share
|
|
Dec 14
2023
|
Helen M. Thackray Chief R&D Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,031
-1.17%
|
$18,186
$6.43 P/Share
|
|
Dec 14
2023
|
Helen M. Thackray Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,000
+16.49%
|
-
|
|
Dec 14
2023
|
Charles K Gayer Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,840
-2.06%
|
$35,040
$6.43 P/Share
|
|
Dec 14
2023
|
Charles K Gayer Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+10.73%
|
-
|
|
Dec 14
2023
|
Jon P Stonehouse President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,592
-1.19%
|
$81,552
$6.43 P/Share
|
|
Dec 14
2023
|
Jon P Stonehouse President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
127,500
+10.04%
|
-
|
|
Dec 14
2023
|
Anthony Doyle Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,475
-2.33%
|
$32,850
$6.43 P/Share
|
|
Dec 14
2023
|
Anthony Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+12.62%
|
-
|
|
Dec 14
2023
|
Alane P Barnes Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,015
-1.34%
|
$24,090
$6.43 P/Share
|
|
Dec 14
2023
|
Alane P Barnes Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,000
+17.58%
|
-
|
|
Nov 30
2023
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
956
+1.85%
|
$4,780
$5.88 P/Share
|
|
Nov 30
2023
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
956
+1.84%
|
$4,780
$5.88 P/Share
|
|
Aug 31
2023
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
791
+1.56%
|
$5,537
$7.11 P/Share
|
|
Aug 31
2023
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
791
+1.56%
|
$5,537
$7.11 P/Share
|
|
Jun 15
2023
|
Machelle Sanders Director |
SELL
Open market or private sale
|
Direct |
4,000
-13.51%
|
$28,000
$7.98 P/Share
|